This is a product review of the use of buprenorphine modified release solution in the maintenance treatment of opioid dependence.
The review discusses pharmacology, dosage, adverse events and key trials. It also provides commentary and recommendations from Dr Shalini Arunogiri, Clinical Lead at Turning Point in Melbourne and Consultant Addiction Psychiatrist.
Please login below to download this issue (PDF)